Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
138 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gilead Sciences, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Gilead Sciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Gilead Sciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Gilead Sciences, Inc. - The report provides overview of Gilead Sciences, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Gilead Sciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Gilead Sciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gilead Sciences, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gilead Sciences, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Gilead Sciences, Inc. Snapshot 6 Gilead Sciences, Inc. Overview 6 Key Information 6 Key Facts 6 Gilead Sciences, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Gilead Sciences, Inc. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Combination Treatment Modalities 14 Pipeline Products - Partnered Products 15 Pipeline Products - Out-Licensed Products 17 Gilead Sciences, Inc. - Pipeline Products Glance 19 Gilead Sciences, Inc. - Late Stage Pipeline Products 19 Gilead Sciences, Inc. - Clinical Stage Pipeline Products 21 Gilead Sciences, Inc. - Early Stage Pipeline Products 23 Gilead Sciences, Inc. - Drug Profiles 25 (emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) 25 (emtricitabine + tenofovir alafenamide fumarate) 26 (sofosbuvir + velpatasvir) 27 tenofovir alafenamide 30 (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) 32 (emtricitabine + GS-9883 + tenofovir alafenamide) 34 (GS-9857 + sofosbuvir + velpatasvir) 35 ambrisentan 37 eleclazine 39 GS-5745 41 idelalisib 43 momelotinib dihydrochloride 46 acalisib 49 entospletinib 50 GS-4774 51 presatovir 52 ranolazine ER 53 regadenoson 56 selonsertib 58 selonsertib + simtuzumab 59 simtuzumab 60 vesatolimod 62 GS-5829 64 GS-5734 65 GS-9674 66 GS-9876 68 ONO-4059 69 GS-459679 71 GS-548202 72 GS-5759 73 GS-607601 74 GS-8374 75 GS-967 76 GS-986 77 Monoclonal Antibodies 1 for Oncology 78 Monoclonal Antibody for HIV / AIDS 79 Monoclonal Antibody to Target HIV-Envelope and CD3 for HIV 80 Px-103 81 Small Molecule to Inhibit Histone Deacetylation for Oncology 82 Small Molecule to Inhibit Histone Methyltransferase for Oncology 83 GS-563253 84 GS-599220 85 Small Molecule for RSV 86 Small Molecule to Inhibit NS4B Protein for HCV 87 Small Molecules for Hepatitis C Infection 88 Small Molecules to Inhibit NS3 Protease for Hepatitis C 89 Small Molecules to Inhibit NS5B for Hepatitis C 90 Gilead Sciences, Inc. - Pipeline Analysis 91 Gilead Sciences, Inc. - Pipeline Products by Target 91 Gilead Sciences, Inc. - Pipeline Products by Route of Administration 94 Gilead Sciences, Inc. - Pipeline Products by Molecule Type 95 Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action 96 Gilead Sciences, Inc. - Recent Pipeline Updates 98 Gilead Sciences, Inc. - Dormant Projects 123 Gilead Sciences, Inc. - Discontinued Pipeline Products 125 Discontinued Pipeline Product Profiles 125 Gilead Sciences, Inc. - Locations And Subsidiaries 129 Head Office 129 Other Locations & Subsidiaries 129 Appendix 134 Methodology 134 Coverage 134 Secondary Research 134 Primary Research 134 Expert Panel Validation 134 Contact Us 134 Disclaimer 135
List of Tables Gilead Sciences, Inc., Key Information 9 Gilead Sciences, Inc., Key Facts 9 Gilead Sciences, Inc. - Pipeline by Indication, 2016 11 Gilead Sciences, Inc. - Pipeline by Stage of Development, 2016 15 Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2016 16 Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2016 17 Gilead Sciences, Inc. - Partnered Products in Pipeline, 2016 18 Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 19 Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2016 20 Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 21 Gilead Sciences, Inc. - Pre-Registration, 2016 22 Gilead Sciences, Inc. - Phase III, 2016 23 Gilead Sciences, Inc. - Phase II, 2016 24 Gilead Sciences, Inc. - Phase I, 2016 25 Gilead Sciences, Inc. - Preclinical, 2016 26 Gilead Sciences, Inc. - Discovery, 2016 27 Gilead Sciences, Inc. - Pipeline by Target, 2016 94 Gilead Sciences, Inc. - Pipeline by Route of Administration, 2016 97 Gilead Sciences, Inc. - Pipeline by Molecule Type, 2016 98 Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2016 99 Gilead Sciences, Inc. - Recent Pipeline Updates, 2016 101 Gilead Sciences, Inc. - Dormant Developmental Projects,2016 126 Gilead Sciences, Inc. - Discontinued Pipeline Products, 2016 128 Gilead Sciences, Inc., Other Locations 132 Gilead Sciences, Inc., Subsidiaries 133
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.